Hypoglycemia Drug Pipeline Analysis Report 2025
Description
Hypoglycemia is a condition characterized by abnormally low blood glucose levels, often affecting individuals with diabetes. It accounts for approximately 95.3% of those diagnosed with type 2 diabetes and 97.4% of individuals with type 1 diabetes globally. The hypoglycemia drug pipeline is expanding rapidly, driven by the demand for better therapies and the growing focus on patient-centric care. Recent advancements include novel glucose-responsive therapeutics and long-acting formulations. With increasing research investments and innovative drug candidates in development, the pipeline of hypoglycemia therapeutics is expected to experience significant growth in the coming years.
Report Coverage
The Hypoglycemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into ypoglycemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypoglycemia. The hypoglycemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypoglycemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypoglycemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypoglycemia.
Hypoglycemia Drug Pipeline Outlook
Hypoglycemia is a condition where blood glucose levels drop below normal, typically below 70 mg/dL. It occurs when there is an imbalance between glucose intake and insulin levels, often due to excessive insulin use, missed meals, or intense physical activity. Symptoms include dizziness, sweating, confusion, and in severe cases, unconsciousness if left untreated.
Hypoglycemia treatments focus on restoring blood glucose levels quickly. Mild cases are treated with fast-acting carbohydrates like glucose tablets or fruit juice. Severe cases may require intravenous glucose or glucagon injections. Long-term management involves adjusting medications, dietary planning, and continuous glucose monitoring to prevent recurring episodes.
Hypoglycemia Epidemiology
Hypoglycemia is a significant concern for individuals with diabetes worldwide. A global study reported hypoglycemia in approximately 95.3% of type 2 diabetes (T2DM) cases and 97.4% of type 1 diabetes (T1DM) cases. In England, hypoglycemia requiring hospitalization is an increasing burden. In Japan, around 20,000 diabetes patients are hospitalized annually for hypoglycemia. In rural India, the prevalence of hypoglycemia is estimated at 57.44%, with 10% experiencing severe cases.
Hypoglycemia – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of hypoglycemia drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total hypoglycemia clinical trials.
Hypoglycemia – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the hypoglycemia pipeline analysis include small molecules, biologics, peptides, gene therapies, cell-based therapies, and others. The hypoglycemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypoglycemia.
Hypoglycemia Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the hypoglycemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypoglycemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypoglycemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypoglycemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypoglycemia drug candidates.
Drug: Avexitide
Avexitide, sponsored by Amylyx Pharmaceuticals Inc., is being evaluated in a Phase III study for post-bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass. It targets GLP-1 receptors to reduce insulin secretion and stabilize blood glucose. The study aims to assess avexitide’s safety and efficacy in reducing hypoglycemic events compared to a placebo.
Drug: Mizagliflozin
Mizagliflozin is an investigational oral, small-molecule drug candidate designed to lower postprandial glucose absorption and insulin secretion. It is a part of a Phase 2 crossover, placebo-controlled study, conducted by Vogenx, Inc., where it is being evaluated for its impact on adverse events and postprandial glucose excursions in post-bariatric hypoglycemia (PBH) patients. The study is anticipated to conclude by May 2025.
Reasons To Buy This Report
The Hypoglycemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypoglycemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypoglycemia collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Hypoglycemia – Pipeline Insight Report
Global Glucose Monitoring Devices Market Report and Forecast
Global Glucose Monitoring Devices Patent Landscape Report
Global Clinical Trials Market
Report Coverage
The Hypoglycemia Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into ypoglycemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypoglycemia. The hypoglycemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypoglycemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypoglycemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypoglycemia.
Hypoglycemia Drug Pipeline Outlook
Hypoglycemia is a condition where blood glucose levels drop below normal, typically below 70 mg/dL. It occurs when there is an imbalance between glucose intake and insulin levels, often due to excessive insulin use, missed meals, or intense physical activity. Symptoms include dizziness, sweating, confusion, and in severe cases, unconsciousness if left untreated.
Hypoglycemia treatments focus on restoring blood glucose levels quickly. Mild cases are treated with fast-acting carbohydrates like glucose tablets or fruit juice. Severe cases may require intravenous glucose or glucagon injections. Long-term management involves adjusting medications, dietary planning, and continuous glucose monitoring to prevent recurring episodes.
Hypoglycemia Epidemiology
Hypoglycemia is a significant concern for individuals with diabetes worldwide. A global study reported hypoglycemia in approximately 95.3% of type 2 diabetes (T2DM) cases and 97.4% of type 1 diabetes (T1DM) cases. In England, hypoglycemia requiring hospitalization is an increasing burden. In Japan, around 20,000 diabetes patients are hospitalized annually for hypoglycemia. In rural India, the prevalence of hypoglycemia is estimated at 57.44%, with 10% experiencing severe cases.
Hypoglycemia – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of hypoglycemia drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Biologics
- Peptides
- Gene Therapies
- Cell-Based Therapies
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total hypoglycemia clinical trials.
Hypoglycemia – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the hypoglycemia pipeline analysis include small molecules, biologics, peptides, gene therapies, cell-based therapies, and others. The hypoglycemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypoglycemia.
Hypoglycemia Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the hypoglycemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypoglycemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypoglycemia clinical trials:
- Vogenx, Inc.
- Amylyx Pharmaceuticals Inc.
- Recordati Group
- Otsuka Pharmaceutical Factory, Inc.
- Zucara Therapeutics Inc.
- Vertex Pharmaceuticals Incorporated
- REMD Biotherapeutics, Inc.
- Seraxis
- Novo Nordisk A/S
- Ultragenyx Pharmaceutical Inc.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypoglycemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypoglycemia drug candidates.
Drug: Avexitide
Avexitide, sponsored by Amylyx Pharmaceuticals Inc., is being evaluated in a Phase III study for post-bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass. It targets GLP-1 receptors to reduce insulin secretion and stabilize blood glucose. The study aims to assess avexitide’s safety and efficacy in reducing hypoglycemic events compared to a placebo.
Drug: Mizagliflozin
Mizagliflozin is an investigational oral, small-molecule drug candidate designed to lower postprandial glucose absorption and insulin secretion. It is a part of a Phase 2 crossover, placebo-controlled study, conducted by Vogenx, Inc., where it is being evaluated for its impact on adverse events and postprandial glucose excursions in post-bariatric hypoglycemia (PBH) patients. The study is anticipated to conclude by May 2025.
Reasons To Buy This Report
The Hypoglycemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hypoglycemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypoglycemia collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Hypoglycemia – Pipeline Insight Report
- Which companies/institutions are leading the hypoglycemia drug development?
- What is the efficacy and safety profile of hypoglycemia pipeline drugs?
- Which company is leading the hypoglycemia pipeline development activities?
- What is the current hypoglycemia commercial assessment?
- What are the opportunities and challenges present in the hypoglycemia drug pipeline landscape?
- What is the efficacy and safety profile of hypoglycemia pipeline drugs?
- Which company is conducting major trials for hypoglycemia drugs?
- Which companies/institutions are involved in hypoglycemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in hypoglycemia?
Global Glucose Monitoring Devices Market Report and Forecast
Global Glucose Monitoring Devices Patent Landscape Report
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Hypoglycemia
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Hypoglycemia
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Hypoglycemia: Epidemiology Snapshot
- 5.1 Hypoglycemia Incidence by Key Markets
- 5.2 Hypoglycemia – Patients Seeking Treatment in Key Markets
- 6 Hypoglycemia: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Hypoglycemia: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Hypoglycemia, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Hypoglycemia Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Hypoglycemia Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Avexitide
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Biological: VX-880
- 10.2.3 Other Drugs
- 11 Hypoglycemia Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Mizagliflozin
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Pasireotide Diaspartate
- 11.2.3 Other Drugs
- 12 Hypoglycemia Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Biological: Volagidemab
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Hypoglycemia Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Hypoglycemia, Key Drug Pipeline Companies
- 14.1 Vogenx, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Amylyx Pharmaceuticals Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Recordati Group
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Otsuka Pharmaceutical Factory, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Zucara Therapeutics Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Vertex Pharmaceuticals Incorporated
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 REMD Biotherapeutics, Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Seraxis
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Novo Nordisk A/S
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Ultragenyx Pharmaceutical Inc.
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
